GEN Exclusives

More »

GEN News Highlights

More »
Jun 8, 2011

FDA Clears Expanded Access Program for Edison’s Mitochondrial Diseases Candidate

  • Edison Pharmaceuticals reported FDA approval of an expanded access program for its EPI-743 candidate in the treatment of seriously ill patients with inherited mitochondrial respiratory chain diseases. Forty patients globally have already been treated with the clinical-stage candidate. Edison separately announced that FDA granted EPI-743 orphan drug designation for the inherited mitochondrial respiratory chain disease indication.

    EPI-743 is an orally absorbed small molecule that crosses into the central nervous system and targets NADPH quinone oxidoreductase 1 (NQO1). Edison says it acts to effectively synchronize energy generation in mitochondria. The firm and its clinical investigators are currently working with FDA and the European Medicines Agency to expedite prospective Phase IIb/III clinical studies.

    Edison is focused on the development of treatments for inherited mitochondrial diseases. The firm is exploiting specialist assays and know-how that facilitate the modeling of redox defects in biological systems for the discovery and optimization of redox-directed drugs. Inherited mitochondrial diseases are clinically diverse and poorly understood, but all share a common defect in how cells make and regulate energy, Edison notes.

    They can be caused by defects in either nuclear or mitochondrial genes, and often lead to central nervous system manifestations. However, Edison notes, mitochondrial diseases can also result in a range of clinical disorders including diabetes, muscle weakness, liver failure, deafness, blindness, and renal insufficiency.

    Estimates vary widely on the incidence of mitochondrial disease worldwide, the firm adds. Conservative estimates put the incidence at about 1–5 people in 10,000, but other estimates place the number of clinically diagnosed mitochondrial disease patients who don’t have a genetic diagnosis at 10 times the number of genetically defined cases.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Patient Access to Genetic Information

Do you think patients have the absolute right to gain access to their own genetic information from medical or clinical laboratories?

More »